I've had the same concerns.
However, my impression was that tech was still underdeveloped and other factors such as how it would function in vivo were still unknown.
For me focusing on the massive amounts of money being poured into the CAR-T sector is an uncomfortable and possibly unhealthy distraction. How can we compete with our own product?
But our own product is only part of the company.
SYC has pushed the selling shovels in a gold rush analogy, which I really like. We don't need to find the gold, we just need to find the people wanting to find the gold.
Starry syndicate powers $165M bet on in vivo CAR-T therapies, enabling Penn spinout Capstan to set sail, page-5
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
-0.001(2.27%) |
Mkt cap ! $34.62M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.5¢ | 4.3¢ | $17.99K | 416.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 152502 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 502504 | 5 |
View Market Depth
| Last trade - 15.59pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.3¢ |
Change
-0.001 ( 4.44 %) |
||||
| Open | High | Low | Volume | ||
| 4.3¢ | 4.5¢ | 4.3¢ | 123400 | ||
| Last updated 15.57pm 17/05/2024 ? | |||||
| PTX (ASX) Chart |